|
|
|
Establishment Labs Holdings Inc (NASDAQ: ESTA) |
|
|
|
| |
Establishment Labs Holdings Inc Outlook |
On February 27 2025 the Establishment Labs Holdings Inc provided following guidance
nnEstablishment Labs Holdings Inc. Reports Fourth Quarter and Full Year 2024 Financial Performance, Reaffirms 2025 Guidancenn
New York - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a leading global medical technology enterprise focused on enhancing women's health and wellness, particularly in the fields of breast aesthetics and reconstruction, has announced its financial results for the fourth quarter and the full year ending December 31, 2024. In this report, the company has reaffirmed its guidance for the year 2025.
nnFourth Quarter Financial Performance and Future Prospectsnn
In the fourth quarter of 2024, Establishment Labs recorded revenues of $44.5 million, aligning with the company’s preannouncement made on January 13. This steady performance underscores the company’s strong market position and operational consistency. Notably, the Motiva Implants, a key product line, received necessary approvals, which is expected to bolster their market penetration moving forward.
While specific financial figures or target metrics for 2025 have not been disclosed in this update, the company affirms its commitment to its previously set goals. This affirmation highlights Establishment Labs' confidence in its strategic initiatives and growth trajectory as they prepare for the upcoming year.
The continued focus on innovation and quality in women's health solutions, alongside the promising market reception of their products, suggests a robust outlook for Establishment Labs as it navigates the evolving landscape of medical technology.
In summary, the reaffirmation of 2025 guidance, combined with solid financial performance in the fourth quarter of 2024, positions Establishment Labs for continued success in the medical technology sector, particularly in women’s health and wellness.,
|
On February 28 2024 the Establishment Labs Holdings Inc provided following guidance
Establishment Labs Holdings Inc., a leading global medical technology company specializing in women's health and wellness, particularly in the areas of breast aesthetics and reconstruction, has released its financial results for the fourth quarter and full year of 2023. In addition, the company has provided guidance for the year 2024.
The company reported a strong performance in the fourth quarter of 2023, with revenue exceeding expectations. For the full year of 2023, Establishment Labs Holdings Inc. reported a significant increase in revenue compared to the previous year.
Looking ahead to 2024, the company has provided guidance with revenue expected to range between $174 million and $184 million. This represents a projected increase of 5% to 11% over the previous year. It is important to note that this guidance does not include revenue from certain sources.
Establishment Labs Holdings Inc. remains committed to its mission of improving women's health and wellness through innovative medical technologies. The company continues to strive for excellence in the field of breast aesthetics and reconstruction, delivering high-quality products and services to its customers around the world.
|
On November 7 2023 the Establishment Labs Holdings Inc provided following guidance
the previous estimate of $162 million. This increase in revenue is primarily driven by growth in the breast aesthetics and reconstruction segments.
During the third quarter, Establishment Labs achieved worldwide revenue of $38.5 million, representing a 0.8% increase compared to the same period last year. This growth can be attributed to the increasing demand for our innovative medical technologies in the field of women's health and wellness, specifically in breast aesthetics and reconstruction.
Looking ahead, we have adjusted our revenue guidance for 2023 to approximately $165 million, reflecting a 2% increase from our previous estimate of $162 million. This upward revision is a testament to the strong performance and consistent growth we have experienced in our target markets.
Our enhanced revenue projection for 2023 is primarily driven by the continued expansion and market penetration of our breast aesthetics and reconstruction products. These products have gained significant traction among healthcare professionals and patients alike, resulting in increased demand and market share.
We remain committed to our mission of improving women's health and wellness, and we are confident that our innovative medical technologies will continue to drive growth and value for our shareholders. With a solid financial foundation and a strong pipeline of new products, we are well-positioned to capitalize on the numerous opportunities in the global medical technology market.
In conclusion, Establishment Labs Holdings Inc. has reported positive financial results for the third quarter of 2023, with a 0.8% increase in worldwide revenue compared to the same period last year. We have also adjusted our revenue guidance for 2023 to approximately $165 million, reflecting a 2% increase from our previous estimate. We are optimistic about the future and remain focused on delivering innovative solutions that improve women's health and wellness.
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
